Combined treatment with regulatory T cells and vascularized bone marrow transplantation creates mixed chimerism and induces donor-specific tolerance to vascularized composite allografts without cytoreductive conditioning

• Published in: The Journal of surgical research 2012-12, Vol.178 (2), p.974-981
• Main Authors: Lin, Jeng-Yee, MD, Tsai, Feng-Chou, MD, PhD, Wallace, Christopher Glenn, MBChB, MS, Huang, Wei-Chao, MD, PhD, Wei, Fu-Chan, MD, Liao, Shuen-Kuei, PhD
• Format: Article
• Language: English
• Subjects: Animals; Bone Marrow Transplantation; CTLA-4 Antigen - physiology; Graft-versus-host disease; Immune Tolerance; Male; Mixed chimerism; Rats; Rats, Inbred BN; Rats, Inbred Lew; Regulatory T cells; Surgery; T-Lymphocytes, Regulatory - immunology; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treg; Vascularized bone marrow transplantation; Vascularized composite allograft
• ISSN: 0022-4804; 1095-8673
• DOI: 10.1016/j.jss.2012.06.061

Abstract Background Cotreatment with regulatory T cells (Treg ) and conventional allogeneic bone marrow transplantation (BMT) successfully induced durable chimerism and tolerance to nonvascularized skin allografts without cytoreductive conditioning in mice. We sought to determine whether Treg treatment combined with vascularized BMT (VBMT) could create mixed chimerism and induce tolerance to vascularized composite allografts (VCAs) without cytoreductive conditioning in rats. Methods Recipient Lewis rats treated (day 0) with or without naturally sorted Treg (3 × 106 ) from Lewis rat spleen and lymph nodes received costimulation blockade (anti-CD154 monoclonal antibody, days 0 and 1 and CTLA-4 immunoglobin, days 2, 4, and 6), rapamycin (days −1, 0, and 2), and concurrent transplantation of fully mismatched allogeneic donor VCAs (day 0) from the Brown Norway rat hindlimb containing VBMT. The mixed chimerism level was assessed monthly using flow cytometry. Survival of VCAs and occurrence of graft- versus -host disease were assessed clinically and histologically. Results The combination of Treg and VBMT treatment led to long-term multilineage hematopoietic mixed chimerism (12–18%) and long-term donor-specific tolerance to VCAs (89% acceptance rate). Neither stable mixed chimerism nor VCA acceptance was observed in recipients without Treg treatment. Graft- versus -host disease did not occur in the VBMT recipients. Conclusions Cotreatment with Treg and VBMT created stable mixed chimerism and induced long-term donor-specific tolerance to VCAs without requiring cytoreductive conditioning. This noncytoreductive Treg -VBMT protocol has potential for clinical application in VCAs.